SINCE THE DISCOVERY OF INTERLEUKIN (IL)-1 as a potent endogenous pyrogen by Charles
. the roles of Ͼ40 interleukins in development, survival, homeostasis, activation, and deactivation of immune cells have been described (45) . The biological importance of those small, soluble proteins is exemplified by human disease caused by the absence of single interleukins (1) or their receptors (2) and the growing therapeutical use of interleukin stimulation (55) or blockade (9) in the clinics. While the name "interleukin" [i.e., between white (blood cells)] suggests a function for interimmune cell communication, many interleukin receptors are expressed by immune and nonimmune cells at the same time. This of course broadens the biological function of interleukins by far but also complicates therapeutical interventions, so that many targeted single interleukin blockers are still generally immunosuppressive (57) . IL-22 differs in this regard and has therefore gathered increasing attention. By now, the role of IL-22 in mucosal immunity against several pathogens is well recognized (59) . Importantly, IL-22 acts mainly through effects on epithelial cells, maintaining barrier integrity or regaining it upon injury. This has led to investigations of IL-22 functions in other epithelioparenchymal organs such as the liver and the kidney. While end-stage renal disease (ESRD) is often defined as widespread kidney fibrosis, this fibrosis is often the consequence of epithelial atrophy. Fostering renal regeneration by epithelial proliferation therefore is one of several promising concepts in the therapy (or avoidance) of ESRD. This review summarizes the available evidence on mechanisms, regulation and possible therapeutical interventions of IL-22 in regeneration. Data on the kidney are preferentially discussed but supported with evidence from other organs based on similar epithelial biology.
IL-22 Biology
IL-22. IL-22 belongs to the IL-10 family of cytokines, which also includes IL-10, IL-19, IL-20, IL-24, IL-26, and the three type III interferons IL-28␣, IL-28␤, and IL-29 (47) . All IL-10 family cytokines share a basic intron/exon structure of five coding exons as well as common structural features. Their primary structures match 13-25% of amino acids with conserved characteristic sequences, and the overall secondary structure of all family members comprises six to seven antiparallel arranged ␣-helices (76) . The human IL-22 gene is located on chromosome 12p15 around 100,000 base pairs upstream to the IFN-␥ locus and consists of 5 exons corresponding to a total length of 5,200 base pairs (73) . The mouse and rat genes are encoded on chromosomes 10 and 7, respectively, with the murine gene encompassing 6 exons. The secreted, monomeric IL-22 proteins of humans and mice both have predicted lengths of 146 amino acids (79% sequence homology), once a 33-amino acid signal peptide is cleaved (46) . The apparent size of mature IL-22 is ϳ17 kDa, as there is the addition of up to three N-linked glycosylation domains.
Cellular sources of IL-22. IL-22 is exclusively produced by cells of the immune system (72) . Well established are cells from the lymphoid compartment, namely, group 3 innate like lymphocytes (ILC3s) (60) and T helper cells with a Th17-or Th22 polarization (16) . In addition, we and others have shown that cells from the myeloid compartment produce IL-22, such as monocytes (Mo), dendritic cells (DCs), and macrophages (M⌽) especially under inflammatory conditions (32, 82) . The stimuli that lead to IL-22 secretion by the aforementioned cells include activation of the transcription factors aryl hydrocarbon receptor (Ahr) (67) by various endogenous (e.g., kynurenins) (43) or exogenous (e.g., dioxine) (15) molecules, ligation of the IL-23 receptor (IL-23R) by IL-23 (81) , and/or activation of Toll-like receptors (e.g., TLR4) (65) .
IL-22 receptor. While immune cells are the source of IL-22, the IL-22 receptor (IL-22R) is mostly expressed by epithelial cells in various tissues with physiologically highest levels in the skin, colonic mucosa, and pancreas, followed by the liver, lung, and kidney (63) . Recent studies showed that also hepatic stellate cells and some fibroblast populations express the IL-22R (4, 24, 26, 29, 42) . The functional IL-22R, like other type II cytokine receptors, consists of two heterodimers, comprising the IL-10R␤2 and the IL-22R␣1 chain (30) , that upon binding of IL-22 dimers undergo ternary complex formation (11) . Whereas IL-10R␤2 has a ubiquitous expression pattern, the narrow IL-22R expression profile stems from limited IL-22R␣1 expression (72) . Of note, also IL-20 (22) and IL-24 (68) can bind the IL-22R, and this binding induces signaling events through the receptor.
IL-22R signaling. The intracellular domains of the IL-22R complex have binding sides for tyrosine kinases Jak1 and Tyk2 (34), as well as for STAT proteins (Fig. 1) . Upon ternary complex formation, the tyrosine kinases phosphorylate STAT3 and to a lesser extent also STAT1 (6) and STAT5 (72) . This allows nuclear translocation and subsequent STAT3-dependent gene expression responses in the target cell (49) . Also, IL-22R ligation induces activation of the phosphoinositide 3-kinase (PI3K)/Akt (44) and the MAP kinase pathways (34) . Interestingly, IL-20 is among the genes regulated by STAT3 (75) . As IL-20 is capable of activating the IL-22R, this creates a positive feedback loop. Recently, it has been shown that in addition there is also a negative feedback loop via STAT3-dependent micro (mi) RNA-197 induction, that downregulates IL-22R expression (35) . It is important to note that the specific gene responses triggered by IL-22 depend on the cell type that is accessed.
IL-22 binding protein.
Another important player in IL-22 biology is the soluble IL-22R␣2 chain, also termed IL-22 binding protein (IL-22BP) (14, 31, 79) . Under homeostatic conditions, DCs produce large amounts of IL-22BP (41) and this is inhibited via NLRP3 signaling in inflammation (25) . This process ensures maximal IL-22 effects on epithelia upon injury, while the importance of continuous IL-22 regulation through IL-22BP is exemplified by the fact that the absence of IL-22BP aggravates different murine models of colon cancer (25) .
Biological functions of IL-22. Depending on the cell type targeted, IL-22 signaling induces different response programs (also recently reviewed in Ref. 56 ). These programs can occur in isolation or in combination and are 1) local barrier function enforcement on nonsterile body surfaces, i.e., the production of antimicrobial substances like defensins (17) , mucins (61) , and S100 proteins (74); 2) targeted myeloid cell recruitment via induction of the C-X-C chemokines CXCL1, CXCL2 (5), CXCL5, CXCL8 (71), CXCL9, and CXCL10 (6); 3) systemic inflammation induction via upregulation of acute-phase reactants in hepatocytes (36); 4) cell survival enhancement via downregulation of proapoptotic Bax and Bad (78) and upregulation of antiapoptotic Bcl-2 and Bcl-X L (18) as well as reg genes (23); and 5) supporting cell proliferation via the PI3K/ Akt/mammalian target of rapamycin (mTOR) pathway (44) and upregulation of RBL2, cyclin D1, and CDKN4 (50) . Which programs are executed depends on the downstream mediator that is mainly activated (STATs vs. PI3K/Akt vs. MAPK) and on the presence or absence of specific negative regulators of IL-22R signaling. Mechanisms involved include GSK-3␤-regulated proteasomal degradation of IL-22R␣1 (70) as well as SOCS1/3 (7, 77) and SirT1 (58) expression, which specifically blocks STAT3-dependent IL-22 effects.
IL-22 in Acute Kidney Injury
Necroinflammation. In acute kidney injury (AKI), different noxious stimuli (e.g., ischemia, toxins like cisplatin, autoimmune cells) cause epithelial cell death (39, 64) . This leads to a local release of danger-associated molecular patterns (DAMPs) that ligate pattern recognition receptors of immune and non- immune cells. This process initiates the secretion of proinflammatory cytokines and chemokines, which amplifies the recruitment of neutrophils and proinflammatory macrophages (Fig. 2 ) (27) . Furthermore, the DAMPs from dead cells act on the neighboring, still viable cells and induce different forms of regulated necrosis (RN) (39, 64) . This second wave of cell death through RN and immigrating immune cells amplifies the process of necroinflammation (40) . Therefore, therapeutical considerations on AKI until now have been largely focused on anti-inflammatory approaches. Interestingly, the DAMP signals from dying renal cells also induce IL-22 in the renal mononuclear phagocytes via TLR4 (32) . The outcome of TLR4 signaling in this context is time dependent, so whereas early TLR-4 blockade prevents tubular necrosis, late blockade impairs tubular regeneration. The proregenerative functions of renal M⌽ and DCs are entirely mediated by IL-22, as IL-22 substitution alone is sufficient to secure proper regeneration after M⌽/DC depletion in the healing phase. In another marquee study, Xu et al. (78) showed that both systemic IL-22 overexpression as well as adenoviral IL-22 gene therapy protect mice from renal ischemia-reperfusion injury. They convincingly showed that in renal proximal tubular epithelial cells (RPTECs) IL-22R signaling leads to STAT3 and Akt phosphorylation, and this prevents renal cell death likely via increased Bcl-2 expression and Bad downregulation (78) . Furthermore, in this model IL-22 therapy was able to reduce systemic inflammation and increased survival after severe ischemic injury. In conclusion, DAMPs promote both necroinflammation and regeneration (3). Th17 cells are also potent IL-22 producers (37). In the kidney, those cells have been shown to be proinflammatory and mediate AKI (66) . Whether also Th17 cells have a dual role like M⌽/DCs remains to be determined.
Tubular regeneration. IL-22 has been shown to regulate cutaneous (42) , mucosal (49) , hepatic (52), thymic (13) , and pancreatic (23) regeneration. As late IL-22 administration is still effective in promoting renal function recovery despite already established cell death, a proregenerative effect on the kidney is likely. With increasing evidence for the presence of progenitor cells within the tubular compartment, it will be interesting to see whether such progenitor cells are responsive to IL-22 as well. Data from the liver show that IL-22 promotes stem cell proliferation in both humans and mice (18) . Also in the intestine, IL-22 is involved in stem cell survival (19) . It is therefore tempting to speculate that IL-22 acts in a dual way on renal tubular cells: whereas in RPTECs it inhibits cell death, it could induce proliferation in renal progenitor cells, therefore ensuring optimal recovery from AKI or other forms of tubular injury. If tubular regeneration fails, ultimately CKD with tubular atrophy and interstitial fibrosis develops in patients (8) . IL-22 might not only be involved in chronic-on-acute renal failure, as recently mutations in MUC1, an IL-22-regulated gene, have been identified as a cause of autosomal-dominant tubulointerstitial kidney disease (ADTKD) (28). Table 1 .
Open questions about the IL-22/IL-22R axis in the kidney
What is the specific contribution of IL-22 produced by Th17 cells, known to be key regulators of renal inflammation? Are Th22 cells involved in renal injury and repair? Is IL-22R1 also expressed by renal progenitor cells? Is there a role for IL-22 in renal cellular compartments other than the proximal tubule, e.g., the glomerulus? Is the miRNA-197-IL22 signaling loop involved in renal IL-22 signaling? Is there a role for either IL-22 or IL-22BP in the etiopathogenesis of complement-mediated disorders, e.g., hepatitis C-associated cryoglobulinemic glomerulonephritis? Is there a role for the IL-22/IL-22R axis in in vivo renal carcinoma?
See the text for definitions.
Potential Roles of IL-22 in Kidney Disease Other Than AKI
Based on these data, the role of IL-22 should also be explored in glomerular epithelial injury and regeneration, namely, in podocyte function and potential de novo podocyte formation. Although no published data are yet available on the expression of IL-22R in podocytes, glomerular, endothelial, or mesangial cells, one Korean study found that a single nucleotide polymorphism in the IL-22R␣1 gene associated with increased IL-22R expression is protective against development of IgA nephropathy, a disease affecting mainly the glomerular mesangium (62) . Effects of IL-22 on the renal interstitium also remain to be determined. Recent data in cutaneous wound healing show that in fibroblasts IL-22 drives ECM production and myofibroblast differentiation (42) . Given that TGF-␤, the master regulator of kidney fibrosis, on the other hand suppresses IL-22 production (54), it will be interesting to see how IL-22 affects the pathogenesis of kidney fibrosis. Effects of IL-22 on the third glomerular compartment, the endothelium, are also possible. Even though glomerular endothelial cells don't seem to express IL-22R under physiological conditions (78) , there is one report showing that endothelial cells can express IL-22R (51) . Aside from that, IL-22 induces complement proteins (20) , so an indirect effect in complement-mediated diseases affecting the glomerular endothelium is possible. This might be of interest especially in hepatitis C virusassociated cryoglobulinemic glomerulonephritis, as IL-22 is upregulated in hepatitis C infection (10) . A potential roadmap summarizing open questions regarding IL-22 and its functions in the kidney is provided in Table 1 .
Therapeutic Implications and Limitations
The possibility to institute therapy in already established disease processes would make the IL-22/IL-22R axis an interesting therapeutic target (32) . Other than the therapeutic roles of IL-22 in kidney disease, the capacity of IL-22 to induce regeneration of the thymus bears the potential to reverse immune senescence in elderly patients (13) . In mouse models of the metabolic syndrome, IL-22 protects ␤ cells against oxidative stress, increases both insulin secretion and sensitivity, and restores glycemic control (21, 69) . Recombinant human IL-22 is produced by Generon Pharmaceuticals (Shanghai) and currently under study in a clinical trial for acute pancreatitis. Despite all enthusiasm, caution with the use of IL-22 is warranted. Of note, IL-22 inhibits the growth of renal cell carcinoma cells in vitro and in a subcutaneous tumor graft model in vivo (80) , but single high-dose IL-22 induces an acute-phase response (36) , and chronic, uncontrolled exposure to IL-22 renders multiple organs susceptible to tumorigenesis (25, 38, 48) . Also, in certain inflammatory diseases IL-22 has clear deleterious effects. This has led to clinical trials with IL-22-blocking antibodies in psoriasis and atopic dermatitis (56, 72) . Other diseases with possible IL-22-induced inflammation are rheumatoid arthritis (26) , systemic lupus erythematosus (53) , and many more autoimmune diseases (recently reviewed in Ref. 47) . Based on the available data so far, IL-22 seems to be double-edged sword, which implies its function and potential use are strictly context dependent. Its antiinfective properties (59) are clearly important and include recruitment of immune cells. These cells then can help to restore the inflamed tissue (33), or, if inflammation prevails, have deleterious effects. The putative proregenerative potential of IL-22 has therefore to be cautiously weighed against the risks of inflammation and tumorigenesis.
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